Neurocrine Corp (NBIX) - Market Cap to Earnings

Neurocrine - graphic logo of issuer NBIX

A steady inflow of funds from the sales of key medications provides Neurocrine Biosciences (NBIX) with financial stability. The P/E valuation multiple visualizes this trend, and this indicator equals 23.60. Dominance in the treatment of dyskinesia through patents guarantees premium revenue. However, geopolitical tensions and disruptions in raw material logistics complicate the conduct of global clinical trials and the supply of components.

neurocrine.com (NBIX): Price to Earnings Ratio from 07/04/2022 to 11/18/2026

Comprehensive metric breakdowns and analytics for neurocrine.com (NBIX)

Comprehensive company analysis:Neurocrine Biosciences, Inc. - NBIX
Original product of Neurocrine Biosciences

Investors are assessing the resilience of Neurocrine Biosciences (NBIX) through the lens of the ratio between market value and actual returns. High R&D activity in neurology and endocrinology makes future profits dependent on the success of clinical trials. The ratio of market capitalization to total annual net income, reflected in the company's P/E chart, measures the cost of one dollar of profit. This metric helps determine the extent of the premium paid for the innovative potential of the pipeline.

Key competitors

Price to Earnings Ratio BIIB|P/E Multiple RGC|Axsome Corp - Price to Earnings Multiple|P/E Multiple ACAD (ACADIA Corp)|XENE: Price to Earnings Multiple|Viking Therapeutics Inc - P/E Multiple|Market Cap to Earnings Supernus Pharmaceuticals, Inc.|Catalyst Pharmaceuticals Inc (CPRX) - Price to Earnings Ratio|DNLI (Denali Therapeutics Inc) - Price to Earnings Ratio|Price to Earnings Ratio Harmony Biosciences Holdings, Inc.|Price to Earnings Ratio BHVN|Price to Earnings Ratio AMLX (Amylyx Pharmaceuticals, Inc.)|Market Price to Net Income Ratio TRVI|Price to Earnings Ratio Praxis Precision Medicines, Inc. PRAX|Anavex Corp - Price to Earnings Ratio|CBLL: Price to Earnings Ratio|Company Value to Net Income PRTA (prothena.com)|Alector, Inc. (ALEC) - Price to Earnings Ratio|Price to Earnings Multiple ANNX|Price to Earnings Ratio Omeros Corp.|Neurogene Therapeutics (NGNE) - Business Payback Period|P/E Multiple ACIU|VYGR (Voyager Therapeutics) - Company Value to Net Income|P/E Multiple NMRA (neumoratx.com)|SCLX: Price to Earnings Multiple|TVGN - Price to Earnings Ratio|Market Cap to Earnings Alpha Cognition Inc.|CGTX: P/E Multiple|inhibikase.com (IKT) - P/E Multiple|Price to Earnings Ratio Cassava Sciences Inc|ASRT - Market Cap to Net Income Ratio|Price to Earnings Ratio Coya (COYA)|P/E Multiple VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Price to Earnings Ratio|Business Payback Period Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E Multiple|Business Payback Period alteritytherapeutics.com ATHE|CLNN: P/E Multiple|Market Cap to Earnings PepGen Corp (PEPG)|Price to Earnings Ratio Jupiter Neurosciences, Inc.|RLMD: Company Value to Net Income|P/E Multiple ANVS|Price to Earnings Ratio Grace Tx GRCE|Price to Earnings Ratio Firefly Neuroscience, Inc AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH: Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|NeurAxis Inc. (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical|Passage Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio NEUP (Neuphoria)|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple